Replies to post #46627 on Amarin Corp Plc (AMRN)

[HDGabor]

No, Anchor SPA was written based on the assumption that favorable changes in the lipid profile would translate into a benefit on clinical outcomes.

FDA notified Amarin in October 2013 (rescinded the SPA) that assumption is not enough, "substantial evidence" is necessary to determining the efficacy of V.

[BioChica]

Yes and that is why the Amarin should bring FDA to trial for misconduct and unprofessional behavior. I think the Lawyers are testing the waters with the NCE lawsuit.